RxDoctor Payments Data

Arthur Chow, MD

Cardiovascular Disease · Raleigh, NCNPI 1982604005

Payments from drug & device makers

$1,242in general payments, 2019–2025

Across 53 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Irhythm Technologies, Inc.$202
  • Atricure, Inc.$152
  • Novartis$132
  • Abbott$131
  • Baxter Healthcare$90
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$82
  • plus $453 from 13 others

What the payments were for

  • Food & beverage$1,242100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,242 in reported general payments places this provider in the 35th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$233,756
Medicare patients
1,389
Services billed
3,807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban635$618,104
XareltoRivaroxaban93$99,562
EntrestoSacubitril/Valsartan87$94,162
Repatha SureclickEvolocumab55$58,986
JardianceEmpagliflozin37$40,655
Praluent PenAlirocumab29$28,198
Metoprolol Succinate600$8,150
Dabigatran EtexilateDabigatran Etexilate Mesylate26$7,643
Ranolazine ErRanolazine59$7,231
Atorvastatin Calcium346$3,779
Dofetilide16$3,296
Ezetimibe128$3,138
Flecainide Acetate86$3,112
Propafenone Hcl ErPropafenone Hcl12$3,028
Rosuvastatin Calcium219$2,946

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$618,104635 claims
Johnson & JohnsonXarelto$63$99,56293 claims
NovartisEntresto$132$94,16287 claims
Boehringer IngelheimJardiance$19$40,65537 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →